Accreditors described new programs for artificial intelligence and immunoglobulin services, revised oncology dispensing materials, and more frequent DMEPOS surveys, with differing eligibility, payer recognition, and compliance implications across specialty pharmacy settings.

Conference presenters highlighted gaps in menopause medication coverage and follow-up support, describing opportunities for pharmacist involvement while offering no comparative evidence that employer-sponsored programs improve symptoms, adherence, or workplace outcomes.

Updated infectious diseases guidance addresses resistant gram-negative infections through pathogen-specific treatment pathways, incorporating newer antibiotics and pharmacologic considerations while acknowledging that several preferred approaches rest on limited clinical outcomes data.

Researchers reported changes in brain functional connectivity after adding N-acetylcysteine to ongoing multiple sclerosis treatment, an early imaging signal that requires confirmation in larger studies with defined dosing and clinical outcomes.

Small observational studies linked menopausal hormone therapy with improvements in cognitive and mood symptoms, while a large meta-analysis found no overall dementia association, leaving cognitive treatment benefits insufficiently established.

Among 39 adults who had stopped GLP-1 therapy after substantial weight loss, medically tailored meals and app-based behavioral support were associated with less four-month weight regain than usual care in a small pilot trial.